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UTILITY OF CILOSTAZOL {#sec1-1}
=====================

Prior meta-analyses showed cilostazol with/without aspirin therapy, approved for the prevention of secondary stroke in Asia, significantly reduced the incidence of recurrent ischemic stroke, occurrence of hemorrhagic stroke, and serious vascular events (e.g. myocardial infarction and/ or vascular deaths).\[[@ref1],[@ref2]\] Here, we reviewed the randomized controlled trial (RCT) by Toyoda *et al*. entitled, "Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischemic stroke in Japan: a multicenter, open-label, randomized controlled trial". This study highlights the value of cilostazol combined with other antiplatelet agents (e.g., aspirin or clopidogrel) in the secondary prevention of ischemic stroke in high-risk patients in Japan.

PHYSIOLOGY OF CILOSTAZOL {#sec1-2}
========================

Cilostazol is a selective phosphodiesterase 3A inhibitor which prevents platelet aggregation through increased intracellular cAMP that inhibits phospholipase and cyclooxygenase activities, reducing thromboxane A2 production, and platelet aggregation. Increased cAMP and protein kinase A levels in vascular smooth muscle cells also prevent myosin light chain kinase-mediated vasoconstriction. Further, cilostazol also improves endothelial function, reendothelialization, and vascular smooth muscle cell proliferation.\[[@ref1]\]

METABOLISM OF CILOSTAZOL {#sec1-3}
========================

Cilostazol is metabolized by the cytochrome P450 system. Inhibitors of cytochrome P450 system (such as omeprazole, diltiazem, erythromycin, itraconazole, and ketoconazole) increase active metabolites of this medication, necessitating cilostazol dosage reduction.

SIDE EFFECTS OF CILOSTAZOL {#sec1-4}
==========================

Cilostazol's most common side effects are headaches, tachycardia (contraindicated for those with heart failure), diarrhea, and heat intolerance.

Exclusion criteria {#sec2-4_1}
------------------

Exclusion criteria for using cilostazol included: (1) cardioembolic disease, (2) use of other anticoagulants, (3) contraindications to obtaining MRI scans, (4) prior non- traumatic intracranial hemorrhage, (5) other hemorrhagic diseases, and/or (6) other blood clotting disorders/diatheses.

Cilostazol stroke prevention study (CSPS) trial {#sec2-4_2}
-----------------------------------------------

The CSPS trial was a multicenter, open-label RCT involving 292 hospitals across Japan (2013--2017).\[[@ref3]\] This RCT evaluated the safety of cilostazol as an antiplatelet agent with vasodilatory effects, which, when combined with aspirin or clopidogrel, beneficially impacted the incidence of recurrent stroke and hemorrhage. With 1879 enrolled patients, ranging in age from 20 to 85, they diagnosed those with non-cardioembolic strokes on MRI (e.g., 90% lacunar or atherosclerotic strokes). Inclusion criteria included at least 50% stenosis of intracranial and/or extracranial arteries and at least two major vascular risk factors (e.g., age ≥65, hypertension, diabetes, chronic kidney disease, peripheral artery disease, history of ischemic heart disease, and/or current smoking).

Randomized trial {#sec2-4_3}
----------------

Patients underwent block randomization; each block required at least six subjects per participating hospital. There were 932 patients randomized to dual therapy consisting of cilostazol (e.g., titrated to 100 mg twice daily over 2 weeks to prevent side effects of headaches and/or palpitations), combined with either aspirin or clopidogrel. Alternatively, 947 patients received monotherapy; aspirin 81 mg or 100 mg daily (for weight over 50 kg) or clopidogrel 50 mg or 75 mg daily (for weight over 50 kg). No placebos were used in this open-label study. Further, patients were not blinded to their therapy.

Hemorrhagic complications of RCT utilizing dual therapy versus monotherapy {#sec2-4_4}
--------------------------------------------------------------------------

There were no significant differences in hemorrhagic complications between the dual and monotherapy groups. In addition, blood pressure was equally controlled in both populations. At 1.4 years, 29/932 (3%) patients on dual therapy experienced stroke recurrence versus 64/947 (7%) on monotherapy (HR 0.49, 95% CI 0.31--0.76, *P* = 0.001); 5/932 (\<1%) versus 7/947 (\<1%) experienced hemorrhagic strokes; 8/932 (\<1%) versus 13/947 (1%) experienced severe intracranial hemorrhage; and 9/947 (\<1%) versus 9/932 (\<1%) experienced gastrointestinal bleeding.

Study limitations {#sec2-4_5}
-----------------

This study methodological limitation includes: (1) delays in study recruitment, (2) 344/1879 enrolled discontinued trial medications, withdrew consent, or were lost to follow-up, and (3) 14 patients in the monotherapy group crossed over to the dual therapy arm.

CONCLUSION {#sec1-5}
==========

This RCT, by Toyoda *et al*. demonstrated the safety of dual therapy, consisting of cilostazol/aspirin or cilostazol/clopidogrel, in preventing secondary ischemic stroke in the Japanese population. Further studies are needed to determine whether these findings would generalize to other populations worldwide.
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